Investigator Databank Expands Members and Launches Website
Novartis, Janssen, Merck (MSD outside the United States and Canada), Lilly, and Pfizer have joined with DrugDev in hosting a repository of specific investigator information as part of the Investigator Databank.
Novartis, Janssen, Merck (MSD outside the United States and Canada), Lilly, and Pfizer have joined with DrugDev in hosting a repository of specific investigator information as part of the Investigator Databank. In addition, investigators can now access the Investigator Databank through the launch of http://www.investigatordatabank.org. Through this website, investigators can securely log in, view and add to their information kept on file by the participating pharmaceutical companies or DrugDev.
The new website http://www.investigatordatabank.org enables the upload of standard essential documents such as CVs, GCP training certificates, and non-study specific site profile forms into a global repository, eliminating some of the repetitive, administrative tasks associated with study feasibility, site qualification, and site start-up.
With five member companies now on board, the Investigator Databank has grown to include nearly 180,000 investigators, 50,000 sites and 7,335 studies.
Read the full release here.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
